Roche and the ABPI: What Does it Mean for Self-Regulation?
This article was originally published in SRA
Executive Summary
Roche's decision not to rejoin the UK industry body the ABPI after its six-month suspension for breaching the advertising code of practice has understandably made waves in the sector. After all, Roche is a pillar of the pharmaceutical establishment and its departure will affect both the ABPI's image and its revenues. But are there any implications for the future of self-regulation by the industry, as some have suggested?